Filing Details

Accession Number:
0000950170-24-014119
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-02-12 21:04:28
Reporting Period:
2024-02-08
Accepted Time:
2024-02-12 21:04:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1650648 4D Molecular Therapeutics Inc. FDMT Biological Products, (No Disgnostic Substances) (2836) 473506994
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1920738 Scott Bizily C/O 4D Molecular Therapeutics Inc.
5858 Horton Street #455
Emeryville CA 94608
Chief Legal Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-02-08 1,332 $6.49 3,069 No 4 M Direct
Common Stock Disposition 2024-02-08 1,332 $27.50 1,737 No 4 S Direct
Common Stock Acquisiton 2024-02-08 2,916 $8.04 4,653 No 4 M Direct
Common Stock Disposition 2024-02-08 2,916 $27.50 1,737 No 4 S Direct
Common Stock Acquisiton 2024-02-08 1,996 $15.78 3,733 No 4 M Direct
Common Stock Disposition 2024-02-08 1,996 $27.50 1,737 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2024-02-08 1,332 $0.00 1,332 $6.49
Common Stock Stock Option (Right to Buy) Disposition 2024-02-08 2,916 $0.00 2,916 $8.04
Common Stock Stock Option (Right to Buy) Disposition 2024-02-08 1,996 $0.00 1,996 $15.78
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
17,043 2032-06-17 No 4 M Direct
45,834 2032-08-31 No 4 M Direct
23,004 2032-01-31 No 4 M Direct
Footnotes
  1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.
  2. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
  3. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
  4. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.